Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Department of Medical Oncology and Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Drugs Today (Barc). 2020 Dec;56(12):781-785. doi: 10.1358/dot.2020.56.12.3233362.
Classical Hodgkin's lymphoma (cHL) is an unusual lymphoid neoplasm, and nearly 50% of patients still relapse after standard therapy. Programmed cell death protein 1 (PD-1) signaling plays a vital role in the progression of cHL. Anti-PD-1 antibodies such as nivolumab and pembrolizumab have thus been approved to treat relapsed/refractory (R/R) cHL. Tislelizumab is a humanized IgG4 monoclonal anti- PD-1 antibody. In contrast to other anti-PD-1 antibodies, the Fc fragment of tislelizumab was engineered to improve the efficacy of PD-1 antibody to a certain extent. In the phase II, open-label, single-arm, multicenter study (ClinicalTrials.gov Identifier NCT03209973), tislelizumab proved its efficacy and safety as a new PD-1 inhibitor to treat Chinese patients with R/R cHL, with a high overall response rate of 87.1% including complete response in 62.9% enrolled patients. Both the median progression-free survival and the median duration of overall response were not reached. In this monograph, we have reviewed the main preclinical and clinical findings in the study of tislelizumab for the treatment of R/R cHL.
经典型霍奇金淋巴瘤（cHL）是一种罕见的淋巴肿瘤，近 50%的患者在标准治疗后仍会复发。程序性细胞死亡蛋白 1（PD-1）信号通路在 cHL 的进展中起着至关重要的作用。因此，抗 PD-1 抗体，如纳武利尤单抗和帕博利珠单抗，已被批准用于治疗复发/难治性（R/R）cHL。替雷利珠单抗是一种人源化 IgG4 单克隆抗 PD-1 抗体。与其他抗 PD-1 抗体不同，替雷利珠单抗的 Fc 片段经过工程改造，在一定程度上提高了 PD-1 抗体的疗效。在这项 II 期、开放标签、单臂、多中心研究（ClinicalTrials.gov 标识符 NCT03209973）中，替雷利珠单抗证明了其作为一种新型 PD-1 抑制剂治疗中国 R/R cHL 患者的疗效和安全性，总缓解率高达 87.1%，包括 62.9%入组患者的完全缓解。中位无进展生存期和中位总缓解持续时间均未达到。在本专题中，我们回顾了替雷利珠单抗治疗 R/R cHL 的主要临床前和临床研究结果。
